Supplementary Data S3 from Development of a First-in-Class Click Chemistry–Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial

Answers are grounded in this paper and cite their sources.

• What was the primary endpoint, and how big was the effect?
• What are the main limitations?
• How does this compare with earlier trials?